Eli Lilly, Novo Nordisk and Trump
Digest more
Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...
For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.
Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance ...
Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...
Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback